Company news: Janssen Pharmaceuticals and Novartis

Share this article:

Janssen Pharmaceuticals received a green light from the FDA for anticoagulant Xarelto (rivaroxaban tablets). The approval is for use once daily in preventing deep vein thrombosis after knee or hip replacement surgery. Janssen holds US marketing rights to the blood thinner, and Bayer HealthCare's sales force will support Janssen efforts by detailing Xarelto in certain hospital accounts.

Some statements used by Novartis in a recorded phone script and professional slides touting its Menveo meningitis vaccine were “false and misleading,” the FDA said in an untitled letter to the company posted last Friday. The promotional materials falsely suggest that Menveo is approved for use consistent with an influential federal vaccine panel's recommendations. Regulators requested that Novartis immediately cease dissemination of the materials. A Novartis spokesperson told Reuters its vaccine unit has already done so.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters